ClinicalTrials.gg
RecruitingNCT07853807CNTRACSUpdated Nov 9, 2026

Cognitive Neurocomputational Task Reliability & Clinical Applications Consortium (CNTRACS): Study 1

An interventional study of Motion Perception Task and Sine Wave Speech Task in SCHIZOPHRENIA 1 (Disorder), Schizoaffective Disorder and Healthy Adult Participants, sponsored by Washington University School of Medicine. Recruiting at 5 sites in United States. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Washington University School of Medicine · Not applicable, Interventional, and Basic science

How we know · 2 judgments

Updated Nov 9, 2026Start date movedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
325
Allocation
Not applicable
Ages
18 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 759 studies in Psychotic Disorders with a site in United States — 97 open to participants now, 113 under way, 7 of them phase 3. Psychotic Disorders · United States.

Planned enrollment
53rd of 682
325 · median 60
Started
2026
with 28 others
No phase
338 of 759
57 open now
Primary completion
2031-06
later than 108 of 112 live
Registered
754th of 759
by date

Among the 759 studies in Psychotic Disorders with a site in United States, this one is the 53rd largest by planned enrollment of the 682 interventional ones that give a count, is one of 29 that started in 2026, is one of 338 with no phase, reaches primary completion later than 108 of the 112 other live ones, and was the 754th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

97 of the 759 studies in Psychotic Disorders with a site in United States are open now. Recruiting first, the newest first:

91 more — sign in →

All 97 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 59 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 759 studies in Psychotic Disorders with a site in United States, or all of them as a file.
02

Study summary

In Study 1, investigators will test the ability of each of the seven paradigms to differentiate between schizophrenia (SZ)/schizoaffective disorder (SZA) and matched healthy control subjects (HC) and to predict individual differences in clinical measures of hallucinations and delusions (as well as measures of function). Investigators will also directly compare the tasks in terms of predictive ability and psychometric properties and determine whether the tasks share variance or explain unique variance. This will include determining whether hallucinations and delusions are best explained by separate underlying processes or by a single process. Investigators will also test whether the model-based parameters from these studies are more precise and sensitive than standard behavioral methods for assessing deficits across psychotic disorders and for predicting hallucinations and delusions (Aim 1). Investigators will also validate key model-based parameters against well-characterized neurophysiological measures using electroencephalogram (EEG) (Aim 4). The data from Study 1 will also be used to optimize (e.g., length, floor, and ceiling effects) tasks for Study 2. To generate a sample with sufficient variation in hallucinations and delusions, investigators will recruit the following groups that balance feasibility with clinical relevance: A) healthy controls (HC) [HC, N=125]; B) schizophrenia and schizoaffective disorder [SZ/SZA, N=200]). For Study 1, investigators will ensure that 40 patients are unmedicated. Investigators anticipate a \~20% screen fail/drop-out rate based on our prior Cognitive Neuroscience Test Reliability and Clinical Applications for Schizophrenia Consortium (CNTRACS) studies. Thus, investigators will run an additional 40 SZ/SZA and 15 HC. All sites have experience recruiting patients in each of these groups as indicated by our past successful studies, and the fact that investigators have been able to recruit patients with significant hallucinations and delusions in all groups. Investigators will also validate key model-based parameters against well-characterized neurophysiological measures using electroencephalogram (EEG) (Aim 4). The data from Study 1 will also be used to optimize (e.g., length, floor, and ceiling effects) tasks for Study 2. To generate a sample with sufficient variation in hallucinations and delusions, investigators will recruit the following groups that balance feasibility with clinical relevance: A) healthy controls (HC) [HC, N=125]; B) schizophrenia and schizoaffective disorder [SZ/SZA, N=200]). For Study 1, investigators will ensure that 40 patients are unmedicated. Investigators anticipate a \~20% screen fail/drop-out rate based on our prior Cognitive Neuroscience Test Reliability and Clinical Applications for Schizophrenia Consortium (CNTRACS) studies. Thus, investigators will run an additional 40 SZ/SZA and 15 HC. All sites have experience recruiting patients in each of these groups as indicated by our past successful studies, and the fact that investigators have been able to recruit patients with significant hallucinations and delusions in all groups.

Read the detailed description

Each participant will complete 4 sessions (\~3 hours each) within 3 weeks, as in our prior studies. The first session includes clinical, self-report, proxy function, and community function assessments. Sessions 2-4 are for task and electroencephalogram (EEG) measurements. Each participant will complete 7 tasks across these sessions, while EEG is recorded. Task order will be counterbalanced across sessions. Clinical Assessment and Self-Report: A trained assessor will diagnose participants using the Structured Clinical Interview (SCID-5) for Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) Text Revision 59 (TR59). Clinicians will rate hallucination and delusion symptom severity with the Chicago Hallucinations Assessment Tool (CHAT) and the Brief Psychiatric Rating Scale (BPRS). Investigators will use the Psychotic Symptom Rating Scales (PSYRATS) to evaluate the degree of preoccupation, conviction, distress, and life disruption associated with hallucinations and delusions elicited on the BPRS and CHAT. To address specificity, investigators will administer the Clinical Assessment Interview for Negative Symptoms (CAINS). For self-report, investigators will use the Beliefs about Voices Scale, which assesses attributions about the origin and power of voices, and the Yale Control Over Perceptual Experiences (COPE) scale, which evaluates the extent to which people feel they can exert control over their voices. Investigators also will use the Peters Delusion Inventory to assess the extent of delusional thinking, supplemented by the Green Paranoia Scale to provide additional coverage of persecutory beliefs. To assess specificity, investigators will use the Patient Health Questionnaire (PHQ-9) to assess depression, the Generalized Anxiety Disorder Scale (GAD-7) to assess anxiety, and the Motivation and Pleasure Scale-Self-Report (MAP-SR) to assess anhedonia and motivation. Investigators will conduct a principal components analysis (PCA) on measures of the same construct (e.g., delusions) and perform primary analyses using the first principal component, followed by secondary analyses of specific measures False Discovery Rate (FDR) correction. Community Function: Patients will complete the Specific Levels of Functioning (SLOF) scale, a validated scale of work and community function. National Institute of Mental Health (NIMH) Common Data Elements: Investigators will acquire the additional NIMH Tier 1 Common Data elements (e.g., World Health Organization Disability Assessment Schedule 2 (WHODAS 2.0) \& DSM-5 Symptom Measure). General Cognitive Ability. Investigators will include standard general cognitive measures to assess the specificity of effects beyond general cognitive impairment. Specifically, investigators will include validated online measures from TestMyBrain (https://www.testmybrain.org/using-tmb/research.html; Digit Symbol Coding, Vocabulary, and Matrix Reasoning), as in our prior work in both clinical and healthy populations. Electroencephalogram (EEG) Procedures: During the above tasks, 64-channel EEG will be recorded from Direct Current (DC)-130 Hertz (Hz) using a 500 Hz sampling rate. Offline data preprocessing will be conducted using Matlab toolboxes EEGLAB and ERPLAB, including segmenting, baseline correction, Independent Component Analysis (ICA)-based artifact correction, artifact rejection, and filtering.

03

Conditions studied

  • SCHIZOPHRENIA 1 (Disorder)
  • Schizoaffective Disorder
  • Healthy Adult Participants

Keywords

  • schizophrenia
  • schizoaffective disorder
  • healthy controls
04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General Inclusion

  1. age 18 to 59
  2. no substance disorder in past six months (confirmed with urine drug screens and breathalyzers);
  3. no head injury or neurological disease. 4. Wechsler Test of Adult Reading (WTAR) score =16+.

Group Specific Criteria: Schizophrenia/Schizoaffective Disorder (SZ):

  1. , 5th Edition (DSM-5) diagnosis of schizophrenia or schizoaffective;
  2. no medication changes in prior month or anticipated in the next month or not taking medications
  3. outpatient or partial hospital if unmedicated

Healthy Controls (HC):

  1. no Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) Psychosis or Bipolar Disorder;
  2. no family history of psychosis or bipolar

Exclusion criteria

Exclusion Criteria:

Healthy Controls (HC):

  1. , 5th Edition (DSM-5) Psychosis or Bipolar Disorder diagnosis
  2. Family history of psychosis or bipolar

Schizophrenia/Schizoaffective Disorder (SZ/SZA): additional exclusion criteria for the unmedicated individuals are:

  1. not in acute exacerbation requiring immediate hospitalization or treatment
  2. self-reported medication non-compliance for at least the four previous weeks 3)never having started medications
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
325 participants (estimated)

Interventions

  • BehavioralMotion Perception Task

    Assesses updating of beliefs from new sensory inputs with prior knowledge via perceiving direction changes in random dot motion stimuli

  • BehavioralSine Wave Speech Task

    Measures the degree to which overweighting of prior beliefs impacts processing of sensory inputs (detection of speech).

  • BehavioralVolatility Task

    Measures the updating of priors about the location of a bag drop from a helicopter when the location changes (prediction errors).

  • BehavioralChoice Probabilistic Reversal Task

    Assesses prior belief updating when feedback about obtaining positive outcomes changes (prediction errors).

  • BehavioralKamin Blocking Task

    Examines the role of mismatches between learned priors and new information (prediction errors) in belief formation about event causes.

  • BehavioralMinnesota Trust Game

    Assesses the degree to which people distinguish between their priors about others' motivations, such as selfishness and spite, and impersonal chance in one-shot trust game and dictator games.

  • BehavioralDynamic Trust Game

    Assesses degree to which people learn and update priors about trusting partners from dynamic social feedback (prediction error) in a social exchange game.

06

What researchers measure

Primary outcomes

  1. Motion Perception Task Performance

    With 15 degrees of initial or changed direction vs. the probability of failing to update.

    Time frame: 1 hour

  2. Sine Wave Speech Task Performance

    Percentage of trials coded as speech or not vs Dprime

    Time frame: 1 hour

  3. Volatility Task Performance

    Percent correct bag captures during periods of stability vs. instability - patients worse in both, but particularly impaired in instability vs. Environmental volatility belief parameter

    Time frame: 1 hour

  4. Choice Probabilistic Reversal Performance Task

    in-switch rate - higher in patients, particularly paranoid patients vs. prior on volatility belief updating in response to volatility

    Time frame: 1 hour

  5. Kamin Blocking Task Performance

    number of times they predict allergy following blocked cue vs. prediction errors and learning rates

    Time frame: 1 hour

  6. Minnesota Trust Game Performance

    Percent of trusting choices depending on decision-agent and temptation vs. spite-guilt beliefs estimate

    Time frame: 1 hour

  7. Dynamic Trust Game Performance

    Trust indexed by mean investment versus learning rates

    Time frame: 1 hour

07

Study locations

5 of 5 sites recruiting
08

References and documents

Publications

  • Li C, Boudewyn MA, Barch DM, Carter CS, Frank MJ, Gold JM, MacDonald AW 3rd, Ragland JD, Silverstein SM, Yonelinas A, Luck SJ, Erickson MA. Impacted and preserved sub-domains of cognitive control in schizophrenia. Neuropsychologia. 2026 Sep 9;230:109503. doi: 10.1016/j.neuropsychologia.2026.109503. Epub 2026 May 25. PubMed 42184934 ↗
  • Boudewyn MA, Erickson MA, Winsler K, Barch DM, Carter CS, Frank MJ, Gold JM, MacDonald AW 3rd, Ragland JD, Silverstein SM, Yonelinas AP, Luck SJ. Assessing Trial-by-Trial Electrophysiological and Behavioral Markers of Attentional Control and Sensory Precision in Psychotic and Mood Disorders. Schizophr Bull. 2025 Mar 14;51(2):543-555. doi: 10.1093/schbul/sbae038. PubMed 38616053 ↗
  • MacDonald AW, Patzelt E, Kurth-Nelson Z, Barch DM, Carter CS, Gold JM, Ragland JD, Silverstein SM. Computational modeling of reversal learning impairments in schizophrenia and bipolar disorder reveals shared failure to exploit rewards. J Psychopathol Clin Sci. 2025 Apr;134(3):262-271. doi: 10.1037/abn0000944. Epub 2025 Mar 10. PubMed 40063391 ↗
  • Erickson MA, Boudewyn MA, Winsler K, Li C, Barch DM, Carter CS, Frank MJ, Gold JM, MacDonald AW 3rd, Ragland JD, Silverstein SM, Yonelinas A, Luck SJ. Dysfunctional Alpha Modulation as a Mechanism of Working Memory Impairment in Serious Mental Illness. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 Dec;9(12):1271-1280. doi: 10.1016/j.bpsc.2024.07.022. Epub 2024 Aug 6. PubMed 39117276 ↗
  • Barch DM, Boudewyn MA, Carter CC, Erickson M, Frank MJ, Gold JM, Luck SJ, MacDonald AW 3rd, Ragland JD, Ranganath C, Silverstein SM, Yonelinas A. Cognitive [Computational] Neuroscience Test Reliability and Clinical Applications for Serious Mental Illness (CNTRaCS) Consortium: Progress and Future Directions. Curr Top Behav Neurosci. 2023;63:19-60. doi: 10.1007/7854_2022_391. PubMed 36173600 ↗
  • Boudewyn MA, Erickson MA, Winsler K, Ragland JD, Yonelinas A, Frank M, Silverstein SM, Gold J, MacDonald AW 3rd, Carter CS, Barch DM, Luck SJ. Managing EEG studies: How to prepare and what to do once data collection has begun. Psychophysiology. 2023 Nov;60(11):e14365. doi: 10.1111/psyp.14365. Epub 2023 Jun 14. PubMed 37314113 ↗
  • Rac-Lubashevsky R, Cremer A, Collins AGE, Frank MJ, Schwabe L. Neural Index of Reinforcement Learning Predicts Improved Stimulus-Response Retention under High Working Memory Load. J Neurosci. 2023 Apr 26;43(17):3131-3143. doi: 10.1523/JNEUROSCI.1274-22.2023. Epub 2023 Mar 17. PubMed 36931706 ↗
  • Kwashie AN, Ma Y, Barch DM, Chafee M, Ragland JD, Silverstein SM, Carter CS, Gold JM, MacDonald AW 3rd. Comparing the functional neuroanatomy of proactive and reactive control between patients with schizophrenia and healthy controls. Cogn Affect Behav Neurosci. 2023 Feb;23(1):203-215. doi: 10.3758/s13415-022-01036-6. Epub 2022 Nov 23. PubMed 36418846 ↗
  • Liu RG, Frank MJ. Hierarchical clustering optimizes the tradeoff between compositionality and expressivity of task structures for flexible reinforcement learning. Artif Intell. 2022 Nov;312:103770. doi: 10.1016/j.artint.2022.103770. Epub 2022 Aug 5. PubMed 36711165 ↗
  • Pratt DN, Barch DM, Carter CS, Gold JM, Ragland JD, Silverstein SM, MacDonald AW. Reliability and Replicability of Implicit and Explicit Reinforcement Learning Paradigms in People With Psychotic Disorders. Schizophr Bull. 2021 Apr 29;47(3):731-739. doi: 10.1093/schbul/sbaa165. PubMed 33914891 ↗
  • Geana A, Barch DM, Gold JM, Carter CS, MacDonald AW 3rd, Ragland JD, Silverstein SM, Frank MJ. Using Computational Modeling to Capture Schizophrenia-Specific Reinforcement Learning Differences and Their Implications on Patient Classification. Biol Psychiatry Cogn Neurosci Neuroimaging. 2022 Oct;7(10):1035-1046. doi: 10.1016/j.bpsc.2021.03.017. Epub 2021 Apr 18. PubMed 33878489 ↗
  • Hamid AA, Frank MJ, Moore CI. Wave-like dopamine dynamics as a mechanism for spatiotemporal credit assignment. Cell. 2021 May 13;184(10):2733-2749.e16. doi: 10.1016/j.cell.2021.03.046. Epub 2021 Apr 15. PubMed 33861952 ↗
  • Moran EK, Gold JM, Carter CS, MacDonald AW 3rd, Ragland JD, Silverstein SM, Luck SJ, Barch DM. Both unmedicated and medicated individuals with schizophrenia show impairments across a wide array of cognitive and reinforcement learning tasks. Psychol Med. 2022 Apr;52(6):1115-1125. doi: 10.1017/S003329172000286X. Epub 2020 Aug 17. PubMed 32799938 ↗
  • Pedersen ML, Frank MJ. Simultaneous Hierarchical Bayesian Parameter Estimation for Reinforcement Learning and Drift Diffusion Models: a Tutorial and Links to Neural Data. Comput Brain Behav. 2020 Dec;3(4):458-471. doi: 10.1007/s42113-020-00084-w. Epub 2020 May 26. PubMed 35128308 ↗
  • Ray KL, Ragland JD, MacDonald AW, Gold JM, Silverstein SM, Barch DM, Carter CS. Dynamic reorganization of the frontal parietal network during cognitive control and episodic memory. Cogn Affect Behav Neurosci. 2020 Feb;20(1):76-90. doi: 10.3758/s13415-019-00753-9. PubMed 31811557 ↗
  • Smucny J, Iosif AM, Eaton NR, Lesh TA, Ragland JD, Barch DM, Gold JM, Strauss ME, MacDonald AW, Silverstein SM, Carter CS. Latent Profiles of Cognitive Control, Episodic Memory, and Visual Perception Across Psychiatric Disorders Reveal a Dimensional Structure. Schizophr Bull. 2020 Jan 4;46(1):154-162. doi: 10.1093/schbul/sbz025. PubMed 30953588 ↗
  • Gold JM, Barch DM, Feuerstahler LM, Carter CS, MacDonald AW, Ragland JD, Silverstein SM, Strauss ME, Luck SJ. Working Memory Impairment Across Psychotic disorders. Schizophr Bull. 2019 Jun 18;45(4):804-812. doi: 10.1093/schbul/sby134. PubMed 30260448 ↗
  • Smucny J, Barch DM, Gold JM, Strauss ME, MacDonald AW 3rd, Boudewyn MA, Ragland JD, Silverstein SM, Carter CS. Cross-diagnostic analysis of cognitive control in mental illness: Insights from the CNTRACS consortium. Schizophr Res. 2019 Jun;208:377-383. doi: 10.1016/j.schres.2019.01.018. Epub 2019 Jan 28. PubMed 30704863 ↗
  • Ermel J, Carter CS, Gold JM, MacDonald AW 3rd, Daniel Ragland J, Silverstein SM, Strauss ME, Barch DM. Self versus informant reports on the specific levels of functioning scale: Relationships to depression and cognition in schizophrenia and schizoaffective disorder. Schizophr Res Cogn. 2017 May 9;9:1-7. doi: 10.1016/j.scog.2017.04.001. eCollection 2017 Sep. PubMed 28740827 ↗
  • Barch DM, Carter CS, Gold JM, Johnson SL, Kring AM, MacDonald AW, Pizzagalli DA, Ragland JD, Silverstein SM, Strauss ME. Explicit and implicit reinforcement learning across the psychosis spectrum. J Abnorm Psychol. 2017 Jul;126(5):694-711. doi: 10.1037/abn0000259. Epub 2017 Apr 13. PubMed 28406662 ↗
  • Lopez-Garcia P, Lesh TA, Salo T, Barch DM, MacDonald AW 3rd, Gold JM, Ragland JD, Strauss M, Silverstein SM, Carter CS. The neural circuitry supporting goal maintenance during cognitive control: a comparison of expectancy AX-CPT and dot probe expectancy paradigms. Cogn Affect Behav Neurosci. 2016 Feb;16(1):164-75. doi: 10.3758/s13415-015-0384-1. PubMed 26494483 ↗
  • Ragland JD, Ranganath C, Harms MP, Barch DM, Gold JM, Layher E, Lesh TA, MacDonald AW 3rd, Niendam TA, Phillips J, Silverstein SM, Yonelinas AP, Carter CS. Functional and Neuroanatomic Specificity of Episodic Memory Dysfunction in Schizophrenia: A Functional Magnetic Resonance Imaging Study of the Relational and Item-Specific Encoding Task. JAMA Psychiatry. 2015 Sep;72(9):909-16. doi: 10.1001/jamapsychiatry.2015.0276. PubMed 26200928 ↗
  • Silverstein SM, Harms MP, Carter CS, Gold JM, Keane BP, MacDonald A 3rd, Ragland JD, Barch DM. Cortical contributions to impaired contour integration in schizophrenia. Neuropsychologia. 2015 Aug;75:469-80. doi: 10.1016/j.neuropsychologia.2015.07.003. Epub 2015 Jul 6. PubMed 26160288 ↗
  • Sheffield JM, Repovs G, Harms MP, Carter CS, Gold JM, MacDonald AW 3rd, Daniel Ragland J, Silverstein SM, Godwin D, Barch DM. Fronto-parietal and cingulo-opercular network integrity and cognition in health and schizophrenia. Neuropsychologia. 2015 Jul;73:82-93. doi: 10.1016/j.neuropsychologia.2015.05.006. Epub 2015 May 13. PubMed 25979608 ↗
  • Barch DM, Sheffield JM. Cognitive impairments in psychotic disorders: common mechanisms and measurement. World Psychiatry. 2014 Oct;13(3):224-32. doi: 10.1002/wps.20145. PubMed 25273286 ↗
  • Strauss ME, McLouth CJ, Barch DM, Carter CS, Gold JM, Luck SJ, MacDonald AW 3rd, Ragland JD, Ranganath C, Keane BP, Silverstein SM. Temporal stability and moderating effects of age and sex on CNTRaCS task performance. Schizophr Bull. 2014 Jul;40(4):835-44. doi: 10.1093/schbul/sbt089. Epub 2013 Jul 1. PubMed 23817024 ↗
  • Owoso A, Carter CS, Gold JM, MacDonald AW 3rd, Ragland JD, Silverstein SM, Strauss ME, Barch DM. Cognition in schizophrenia and schizo-affective disorder: impairments that are more similar than different. Psychol Med. 2013 Dec;43(12):2535-45. doi: 10.1017/S0033291713000536. Epub 2013 Mar 25. PubMed 23522057 ↗
  • Keane BP, Silverstein SM, Barch DM, Carter CS, Gold JM, Kovacs I, MacDonald AW 3rd, Ragland JD, Strauss ME. The spatial range of contour integration deficits in schizophrenia. Exp Brain Res. 2012 Aug;220(3-4):251-9. doi: 10.1007/s00221-012-3134-4. Epub 2012 Jun 19. PubMed 22710617 ↗
  • Barch DM, Mathalon DH. Using brain imaging measures in studies of procognitive pharmacologic agents in schizophrenia: psychometric and quality assurance considerations. Biol Psychiatry. 2011 Jul 1;70(1):13-8. doi: 10.1016/j.biopsych.2011.01.004. Epub 2011 Feb 21. PubMed 21334602 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Our plan is to share de-identified participant data through the National Data Archive (NDA) as required by the National Institute of Mental Health (NIMH)

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jun 2031, 55 months later.

Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 55 months is above that.

Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2026
First posted
Oct 2, 2026
StartEst.
Nov 15, 2026was Oct 2026
Primary completionEst.
Jun 30, 2031
CompletionEst.
Jun 30, 2031
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2026→Nov 15, 2026
Nov 9, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of Minnesota · Minneapolis, United StatesContact z•••@umn.edu · •••1275→C•••@umn.edu · •••1275
Nov 9, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 2 updates
  1. Nov 9, 2026
    Start date Oct 1, 2026→Nov 15, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Minnesota · Minneapolis, United StatesContact z•••@umn.edu · •••1275→C•••@umn.edu · •••1275
  2. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07853807
Responsible party
Deanna Barch (Professor of Psychological & Brain Sciences Professor of Radiology , Gregory B. Couch Professor of Psychiatry, Washington University School of Medicine) — Principal investigator
First posted
Oct 2, 2026
Start date
Nov 15, 2026 (estimated)
Primary completion
Jun 30, 2031 (estimated)
Completion
Jun 30, 2031 (estimated)
Last update
Nov 9, 2026

Study contacts

Deanna Barch, Ph.D.
Contact
dbarch@wustl.edu
314-935-8729
Clinical Coordinator
Contact
ingram@wustl.edu
314-747-2160
Deanna Barch, Ph.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion